A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors
Authors
Keywords
-
Journal
PLoS One
Volume 12, Issue 6, Pages e0178593
Publisher
Public Library of Science (PLoS)
Online
2017-06-06
DOI
10.1371/journal.pone.0178593
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).
- (2017) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma
- (2016) Brian H. Kushner et al. INTERNATIONAL JOURNAL OF CANCER
- Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model
- (2015) Diane E. Cole et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Toxicity evaluation of convection-enhanced delivery of small-molecule kinase inhibitors in naïve mouse brainstem
- (2015) Zhiping Zhou et al. CHILDS NERVOUS SYSTEM
- Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent
- (2015) Jie Shen et al. TUMOR BIOLOGY
- Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia
- (2015) Alice Cani et al. Oncotarget
- Perifosine as a potential novel anti-telomerase therapy
- (2015) Brody Holohan et al. Oncotarget
- PI3K/AKT signaling pathway and cancer: an updated review
- (2014) Miriam Martini et al. ANNALS OF MEDICINE
- Current View on the Mechanism of Action of Perifosine in Cancer
- (2014) Joachim Fensterle et al. Anti-Cancer Agents in Medicinal Chemistry
- A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms
- (2014) William D. Figg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
- (2014) L Molife et al. Journal of Hematology & Oncology
- Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
- (2014) R. Dienstmann et al. MOLECULAR CANCER THERAPEUTICS
- Disruption of astrocyte–vascular coupling and the blood–brain barrier by invading glioma cells
- (2014) Stacey Watkins et al. Nature Communications
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere
- (2013) Jing Li et al. Journal of Translational Medicine
- Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial andin vitrostudies
- (2013) Daphne R. Friedman et al. LEUKEMIA & LYMPHOMA
- Anticancer mechanisms and clinical application of alkylphospholipids
- (2012) Wim J. van Blitterswijk et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
- (2012) T. Sangai et al. CLINICAL CANCER RESEARCH
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome
- (2012) S. Mueller et al. NEURO-ONCOLOGY
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
- (2011) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Tissue concentration of systemically administered antineoplastic agents in human brain tumors
- (2011) Marshall W. Pitz et al. JOURNAL OF NEURO-ONCOLOGY
- First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours
- (2010) Clemens Unger et al. EUROPEAN JOURNAL OF CANCER
- Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children’s Oncology Group
- (2010) Ian F. Pollack et al. JOURNAL OF NEURO-ONCOLOGY
- In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor Perifosine
- (2010) Z. Li et al. JNCI-Journal of the National Cancer Institute
- Heterozygosity for Pten Promotes Tumorigenesis in a Mouse Model of Medulloblastoma
- (2010) Robert C. Castellino et al. PLoS One
- Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy
- (2009) L. Fu et al. CANCER RESEARCH
- The Alkylphospholipid Perifosine Induces Apoptosis and p21-Mediated Cell Cycle Arrest in Medulloblastoma
- (2009) A. Kumar et al. MOLECULAR CANCER RESEARCH
- Protein Expression of Platelet-Derived Growth Factor Receptor Correlates with Malignant Histology and PTEN with Survival in Childhood Gliomas
- (2008) H. K. Thorarinsdottir et al. CLINICAL CANCER RESEARCH
- PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo
- (2008) D. Hambardzumyan et al. GENES & DEVELOPMENT
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now